Page 10 - Evofem Bioscience News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Evofem Biosciences Reports First Quarter 2021 Financial Results and Provides Corporate Update -- Net Revenues Increased 550% Compared to 2020 Fourth Quarter -- -- Over 5,000 Healthcare Providers have Prescribed Phexxi to Date -- -- Management to Host Conference Call Today, Thursday, May 6, 2021, at 4:30 p.m. ET -- News provided by Share this article Share this article SAN DIEGO, May 6, 2021 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) ("Evofem" or the "Company"), today reported financial results for the three-month period ended March 31, 2021. First quarter and recent highlights...

Evofem Biosciences Announces Presentation of Two New Phexxi Data Sets at the 2021 American College of Obstetricians and Gynecologists Annual Meeting News provided by Share this article Share this article SAN DIEGO, April 28, 2021 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that two new data sets from its Phase 3 AMPOWER trial evaluating ® (lactic acid, citric acid, potassium bitartrate) will be presented at the 2021 American College of Obstetricians and Gynecologists (ACOG) Annual Clinical and Scientific Meeting (ACSM). The meeting will be conducted virtually...

Evofem Biosciences' DTC Campaign "Get Phexxi" Delivers Strong Initial Impact - Over 2,400 Phexxi units dispensed in February 2021, up 30% from prior month - - Accelerating retail demand drove 73% increase in ex-factory sales month-over-month - - Ex-factory sales YTD 2021 through mid-March have exceeded FY 2020 levels - News provided by Share this article Share this article SAN DIEGO, March 17, 2021 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that "Get Phexxi," its national direct-to-consumer (DTC) campaign aimed at broadening awareness of its non-hormonal, on-d...

Evofem Biosciences Announces Publication in American Journal of Obstetrics and Gynecology of AMPREVENCE Study of EVO100 for Chlamydia and Gonorrhea Prevention News provided by Share this article Share this article SAN DIEGO, March 16, 2021 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced publication of the pivotal manuscript from the AMPREVENCE clinical trial in the highly respected American Journal of Obstetrics and Gynecology (AJOG). This double-blinded, placebo-controlled, multicenter study of EVO100 met its primary and secondary efficacy endpoints with statistica...

Evofem Biosciences Wins Business Intelligence Group's BIG Innovation Award 2021 Evofem honored amongst best companies globally for outstanding innovation with first-in-class non-hormonal prescription contraceptive vaginal gel, Phexxi® News provided by Share this article Share this article SAN DIEGO, Jan. 12, 2021 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) has been named a winner of Business Intelligence Group's 2021 BIG Innovation Awards for outstanding innovation with first-in-class non-hormonal prescription contraceptive vaginal gel, Phexxi® (lactic acid, citric acid and...